Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
Athan Spiros1, Robert Carr1, Hugo Geerts1,21In Silico Biosciences, Berwyn, PA, USA; 2School of Medicine, University of Pennsylvania, PA, USAAbstract: Species differences in physiology and unique active human metabolites contribute to the limited predictive value of preclinical rodent models for many...
Guardado en:
Autores principales: | Athan Spiros, Robert Carr, Hugo Geerts |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dbfab43968d34192ba8f1f3adc8a528e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Active-state model of a dopamine D2 receptor-Gαi complex stabilized by aripiprazole-type partial agonists.
por: Ralf C Kling, et al.
Publicado: (2014) -
Phasic dopamine reinforces distinct striatal stimulus encoding in the olfactory tubercle driving dopaminergic reward prediction
por: Lars-Lennart Oettl, et al.
Publicado: (2020) -
Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter
por: Mark D. Condon, et al.
Publicado: (2019) -
The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto K, et al.
Publicado: (2014) -
Nolz1 expression is required in dopaminergic axon guidance and striatal innervation
por: Clement Soleilhavoup, et al.
Publicado: (2020)